Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04832620
Other study ID # 41335
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 2, 2021
Est. completion date December 2027

Study information

Verified date November 2023
Source Leiden University Medical Center
Contact Stijn Krol, dr. PhD
Phone +31624539398
Email A.D.G.Krol@lumc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Rationale: Chordomas and chondrosarcomas located in the axial skeleton are malignant neoplasms of bone. These tumors share the same clinical challenges, as the effect of the disease is more a function of their local aggressiveness than their tendency to metastasize (20% metastasize). The local aggressive behavior can cause debilitating morbidity and mortality by destruction of nearby located critical neurovascular structures. Imaging has, in addition to histopathology, a role in diagnosis and in guiding (neo)adjuvant and definitive treatment. Despite the low sensitivity to radiotherapy, proton radiotherapy has been successfully used as an adjunct to resection or as definitive treatment for aggressive chordomas and chondrosarcomas, making it a standard indication for proton therapy in the Netherlands. Chordomas and chondrosarcomas consist, especially after previous therapy, of non-viable and viable tumor components. Identification of these viable components by functional imaging is important to determine the effect of previous therapy, as change in total tumor volume occurs more than 200 days after change of functional imaging parameters. Objective: The main objective of this study is to determine if functional MRI parameters change within 6 months, and earlier than volumetric changes after start of proton beam therapy. This would allow timely differentiation between affected and unaffected (viable) tumor components, which can be used for therapy adjustment. Secondary objectives: Determine which set of parameters (PET-CT and secondary MRI) can predict clinical outcome (tumor specific mortality, development of metastases, morbidity secondary to tumor activity and morbidity secondary to treatment); determine what type of imaging can accurately identify viable tumor nodules relative to critical anatomical structures; improving understanding of relevance of changing imaging parameters by correlating these with resected tumor. Study design: Prospective cohort study Study population: LUMC patients diagnosed with primary or recurrent chordoma or chondrosarcoma in the axial skeleton. A number of 20 new patients per year is expected. Main study parameters: Volumetric and functional MR imaging parameters including permeability parameters. Secondary parameters are generated by PET-CT (SUV, MTV and TLG), MR (perfusion, permeability and diffusion), therapy (proton beam dose mapping, surgery) and clinical outcome. End points are disease specific survival, progression free survival (including development of metastases), side effects of treatment, and functional outcome (see CRF). In patients who are treated with surgical resection following neo-adjuvant therapy, the surgical specimen will be correlated with imaging findings. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Treatment and clinical management will not be affected in this study, thus the additional burden, risks, and benefits associated with participation in this study are minimal. Two extra MRI and one PET-CT examination will be planned during proton therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 2027
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Histologically diagnosed with primary or recurrent chordoma or chondrosarcoma in the axial skeleton (clivus, spine and sacrum) - Accepted for standard proton beam therapy Exclusion Criteria: - Diagnosis other than chordoma or chondrosarcoma is made. - Patient refuses (parts) of the standard treatment protocol. - Patient refuses MRI due to claustrophobia. - Patient not suitable for MRI due to the presence of MRI incompatible implants. - Incapacitated patients. - Patient doesn't allow coded data to be used for analysis. - Patient is under 50 years of age. - Lesion size less than 1cm. - Patients with WHO 3 and higher.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands HollandPTC Delft South Holland
Netherlands LUMC Leiden South Holland

Sponsors (3)

Lead Sponsor Collaborator
Leiden University Medical Center HollandPTC, Varian Medical Systems

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Vp(max), Vp(min) MRI permeability parameter - tumor plasma volume At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary Rel Enhancement (%) MRI perfusion parameter showing the signal enhancement of a pixel of certain dynamic relative to that same pixel in the reference dynamic. The reference dynamic is normally the first, pre-contrast dynamic. At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary Max Enhancement (%) MRI perfusion parameter showing difference between peak intensity S1 and S0. At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary Max Rel Enhancement (%) MRI perfusion parameter showing maximum of all relative enhancements over all dynamics At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary Time of arrival T0 (s) MRI perfusion parameter showing time at which the signal intensity increases for at least 20% compared to the baseline (referred to as initial signal intensity S0).
The baseline is the average of the signal intensities of all timepoints before the contrast uptake starts.
At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary Time To Peak (s) MRI perfusion parameter showing time till contrast agent bolus reaches peak intensity At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary Wash In Rate (s¯¹) MRI perfusion parameter showing maximum slope between T0 and time of peak intensity T1 At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary Wash Out Rate (s¯¹) MRI perfusion parameter showing maximum slope between time of peak intensity T1 and the end of the measurement At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary Brevity of Enhancement (s) MRI perfusion parameter showing time between point of maximum wash in rate and maximum wash out rate. At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary Ktrans MRI permeability parameter - transfer constant between blood plasma and Extravascular Extracellular Space (EES), also called vascular permeability At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary kep MRI permeability parameter showing rate between EES and blood plasma (also called Tracer Efflux Rate) At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary Ve MRI permeability parameter showing Extravascular Volume fraction (Leakage space); defined as Ktrans / kep At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary Area under the curve (AUC) MRI permeability and perfusion parameter showing area Under the Curve of all time curves At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary mean ADC, Min ADC, Max ADC MRI diffusion parameters At inclusion, 4 and 8 weeks, 5,11,17 and 23 months after the start date of proton therapy treatment
Secondary SUV Standard uptake value extracted from PET-CT imaging At inclusion and and 11 months following the start date fo proton therapy
Secondary MTV Metabolic tumor volume extracted from PET-CT imaging At inclusion and and 11 months following the start date fo proton therapy
Secondary TLG Total lesion glycolysis extracted from PET-CT imaging At inclusion and and 11 months following the start date fo proton therapy
See also
  Status Clinical Trial Phase
Recruiting NCT03785171 - Predicative Value of Multimodal MRI in Moyamoya Disease
Not yet recruiting NCT03726788 - Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis Phase 2
Active, not recruiting NCT01956409 - Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis Phase 4
Completed NCT01660841 - Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging Phase 3
Recruiting NCT03635619 - The Application of 3T MRI in Esophageal Cancer
Recruiting NCT03658343 - T2* MRI Analysis for Sarcoma N/A
Recruiting NCT04555642 - Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
Active, not recruiting NCT03441867 - Neuroimaging Biomarker for Seizures N/A
Recruiting NCT04850001 - Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study
Not yet recruiting NCT05816213 - Point-of-care Low-field MRI in Acute Stroke
Active, not recruiting NCT05498623 - MR Fingerprinting for Diagnostic of Prostate Cancer
Recruiting NCT04257747 - Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI N/A
Recruiting NCT04996615 - Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women
Recruiting NCT05889117 - Brain Stimulation for Concussion N/A
Completed NCT02540967 - Drug Use Investigation of Gadovist.
Completed NCT05103189 - 4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension N/A
Completed NCT02567318 - Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia? N/A
Recruiting NCT02834585 - Magnetic Resonance Imaging or Ultrasound in Soft Tissue Tumors (MUSTT) N/A
Active, not recruiting NCT02446665 - Disease Status in Primary Sclerosing Cholangitis by Elastography N/A
Completed NCT01721785 - Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer N/A